Company intelligence / Profile preview

Correvio Pharma Corp.

Vancouver, British Columbia, Canadacrglp.com ↗

Ownership: Private
Employees: ~27
Development stage: Commercial

Overview

Correvio Pharma was a specialty pharmaceutical company that commercialized hospital drugs with a focus on cardiovascular therapies. The company had two marketed in-hospital cardiology products: BRINAVESS (vernakalant HCl) for atrial fibrillation and AGGRASTAT (tirofiban HCl) for acute coronary syndrome. It also had licensed medicines including XYDALBA (dalbavancin hydrochloride) and ZEVTERA/MABELIO (ceftobiprole medocaril)[3][6].

Therapeutic areas: CardiovascularInfectious Diseases
Modalities: Small molecule drugsChemical drugs
Industry: Biotech

Drug pipeline

5 assets

vernakalant

Commercial

Indications: Atrial fibrillation

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Correvio Pharma Corp..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Correvio Pharma Corp..

Explore the full profile